The U.S. FDA has approved Moderna’s mFLUSIVA, making it the first mRNA-based influenza vaccine, for adults ages 50 and older. The shot also received accelerated approval for adults ages 65 and older. Experts say the vaccine adds an important new option for flu prevention, rather than replacing existing flu vaccines.